Hygea VCT plc :Net Asset Value

For immediate release                                                                                                                 14 May 2015

HYGEA VCT PLC

The Board of Hygea  vct plc ('the company') announces that at 30 April 2015 the unaudited Net Asset Value per  Ordinary Share ('NAV') was  82.7p (31 December 2014: 90.4p). However the Board is pleased to see the significant increases in the bid prices of Scancell plc and EKF Diagnostics Holdings plc shares at close of business on 13 May 2015 which were 30.5p and 23.5p per share respectively. Adjusting only for the increase in the value of these two investments, the NAV at 13 May 2015 based on those bid prices (net of performance fee) would have been 88.7p.

In arriving at this NAV the following valuations are relevant:-

The company's holding of 13,249,730 Scancell plc shares has been valued at 26.25p per share (31 December 2014: 32p.)

The company's holding of 2,431,768 Omega Diagnostics plc shares has been valued at 19.88p per share (31 December 2014: 18.38p.).

The company's holding of 1,285,552 EKF Diagnostics Holdings plc shares has been valued at 19.5p per share (31 December 2014: 21.25p.).

There have been no changes to the valuation of the unquoted portfolio since 31 December 2014.

The company had used £50,000 of its overdraft facility of £100,000 at 30 April 2015.

The Board is pleased to report the following in respect of the portfolio:-

• Hallmarq Veterinary Imaging Limited was one of only two companies awarded the Queen's Award for Enterprise in April 2015 for both Innovation and International Trade.
• Epistem's Genedrive (a point of care molecular diagnostic instrument) has been licensed for importation into India for use in diagnosing TB.

• OR Productivity plc has achieved record sales of consumables in the UK in the quarter to 31 March 2015, resulting in the UK business breaking even at a marginal level during the quarter for the first time.
   
• EKF Diagnostics Holdings plc and Scancell plc both had posters accepted for presentation at the April 2015 annual meeting of American Association for Cancer Research.

Enquiries:

Charles Breese, Hygea VCT plc on 01280 703482 or [e-mail]

Roland Cornish, Beaumont Cornish Limited on 020 7628 3396

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Hygea VCT plc via Globenewswire

HUG#1921675